The first patients to receive Intellia's CRISPR-based therapy for hereditary angioedema saw their swelling attacks virtually ...

AstraZeneca is having another big ASCO, but the art of comfort care for cancer patients also got a plenary session.

When palliative care is delivered via telehealth, there are a number of advantages. They can be at home, in their pajamas, ...

AstraZeneca reports at ASCO that its drug Tagrisso slowed down lung cancer progression for a median of several years in stage ...

The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago — is ...

At ASCO, Astra Zeneca reported that its drug Enhertu stalled the growth of tumors by more than a year in women with the most ...

The Biden administration has significantly opened the door to drug treatment strategies that help reduce substance use, even ...

Recap: Today's top stories from ASCO 2024 include updates on safety data about a myelofibrosis candidate, and record ...

At an ASCO 2024 event, Richard Pazdur, the FDA's top oncologist, said the agency wants to see companies conducting studies ...

At a STAT event, oncology leaders spoke of advances that are turning old ideas like antibody-drug conjugates into broadly ...

Corbus, reporting on early trials of its antibody-drug conjugate, says it "seems to be clinically effective in bladder cancer ...

The effectiveness and safety of MDMA-assisted therapy for post-traumatic stress disorder will be scrutinized soon by FDA ...